- |||||||||| Ajovy (fremanezumab) / Otsuka, Teva, Aimovig (erenumab-aooe) / Amgen, Novartis
Journal, Adverse events: Drug-related side effects and adverse reactions in the treatment of migraine: a bibliometric and visual analysis. (Pubmed Central) - Feb 21, 2024
Furthermore, it is imperative to enhance the assessment of clinical trial outcomes, consistently monitor the efficacy and safety of prominent drugs such as Erenumab and Fremanezumab. There is a need for further evaluation of acute and preventive treatments tailored to different populations and varying types of migraine.
- |||||||||| Aimovig (erenumab-aooe) / Amgen, Novartis
New trial, Real-world evidence, Real-world: Migraine Survey in Gulf Region (clinicaltrials.gov) - Feb 15, 2024
P=N/A, N=200, Not yet recruiting,
- |||||||||| Emgality (galcanezumab-gnlm) / Eli Lilly, Daiichi Sankyo, Organon, Ajovy (fremanezumab) / Otsuka, Teva, Aimovig (erenumab-aooe) / Amgen, Novartis
Journal: Effect of anti-CGRP-targeted therapy on migraine aura: Results of an observational case series study. (Pubmed Central) - Feb 13, 2024
Conversely, these antibodies are able to counteract, via their peripheral mechanisms of action, the sensitization of the trigemino-vascular pathway which is triggered by CSD. This aforementioned might explain why in our patients, migraine aura attacks remained unchanged in their frequencies, but the headache phases were either reduced or absent.
- |||||||||| Journal, Adverse events, Real-world evidence, Real-world: Adverse event reporting of four anti-Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: a real-world study based on the FDA adverse event reporting system. (Pubmed Central) - Jan 24, 2024
In addition, there are new AEs that were not listed in the drug instructions but occurred concurrently with multiple drugs, such as Raynaud's phenomenon, weight increase, menstrual disorders, throat tightness, and paraesthesia oral. Common AE signals of the four anti-CGRP mAbs and new AE signals were found to provide a reference for clinical drug selection in clinical practice.
- |||||||||| Emgality (galcanezumab-gnlm) / Eli Lilly, Daiichi Sankyo, Organon, Ajovy (fremanezumab) / Otsuka, Teva, Aimovig (erenumab-aooe) / Amgen, Novartis
Retrospective data, Journal, Real-world evidence, Real-world: Characteristics associated with response to subcutaneously administered anti-CGRP monoclonal antibody medications in a (Pubmed Central) - Jan 22, 2024
Active, not recruiting --> Completed In this real-world setting, anti-CGRP preventives reduced MDM persistently and had similar and large effect sizes on MDM reduction; however, clinical and genetic factors influenced response.
- |||||||||| Ajovy (fremanezumab) / Otsuka, Teva, Aimovig (erenumab-aooe) / Amgen, Novartis
Observational data, Journal, Real-world evidence, Real-world: No wearing-off effect of erenumab or fremanezumab for chronic migraine prevention: a single-center, real-world, observational study. (Pubmed Central) - Jan 16, 2024
There was no wearing-off in treatment responders, which is in alignment with premarketing data from placebo-controlled phase III studies. These data suggest that patients should be informed upfront that no wearing-off effect is expected because anxiety for attacks at the end of the month per se may generate migraine attacks.
- |||||||||| Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Clinical, Retrospective data, Journal, Real-world evidence, Real-world: Combination of anti-CGRP/CGRP-R mAbs with onabotulinumtoxin A as a novel therapeutic approach for refractory chronic migraine: a retrospective study of real-world clinical evidence and a protocol for a double-blind, randomized clinical trial to establish the efficacy and safety. (Pubmed Central) - Dec 28, 2023
The mAbs chosen are: erenumab, because its combination effect with onabotulinumtoxin A improved symptoms in 65% of patients; eptinezumab, due to its faster action. The results highlight that early diagnosis of migraine improves therapeutic outcomes with mAbs alone, confirming their effectiveness and the need for an adequately powered clinical trial evaluating the safety and potential superior effectiveness of eptinezumab/erenumab and onabotulinumtoxin A together.
- |||||||||| Ajovy (fremanezumab) / Otsuka, Teva, Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap, Aimovig (erenumab-aooe) / Amgen, Novartis
Review, Journal: Treatment Options for Posttraumatic Headache: A Current Review of the Literature. (Pubmed Central) - Dec 22, 2023
A randomized crossover study of 40 patients with persistent PTH found that onabotulinum toxin-A decreased cumulative number of headaches/week by 43.3% in the treatment group and increased by 35.1% among placebos...New studies indicate promise in improving clinically important outcomes of PTH. However, more research is necessary to determine the optimal treatment and whether combining pharmacologic and nonpharmacologic treatment versus a single modality is more effective.
- |||||||||| Emgality (galcanezumab-gnlm) / Eli Lilly, Daiichi Sankyo, Ajovy (fremanezumab) / Otsuka, Teva, Aimovig (erenumab-aooe) / Amgen, Novartis
Journal: Comparative Study of the Efficacy of Anti-CGRP mAbs on Migraineurs: Analysis of the First Year of Therapy, 1-Month Suspension Period, and Reprisal. (Pubmed Central) - Dec 9, 2023
In our study, the three anti-CGRP mAbs presented a similar response, with no significant differences, during the first year of therapy, the suspension period, and 3 months after the drug reprisal. The response rate during the 1-month suspension period in chronic migraineurs may be higher with galcanezumab.
- |||||||||| Aimovig (erenumab-aooe) / Amgen, Novartis
Reimbursement, US reimbursement, Journal, Real-world evidence, Real-world: Impact of a reimbursement policy change on treatment with erenumab in migraine - a real-world experience from Germany. (Pubmed Central) - Oct 30, 2023
Starting erenumab earlier in the course of migraine progression in a real-world setting may lead to a better response than starting after multiple failed prophylactic attempts. Continually gathering real-world evidence may help policymakers in deciding how readily to cover CGRP-targeted therapies in migraine prevention.
- |||||||||| Review, Journal: Efficacy and Safety of Anti-calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibodies in Preventing Migraines: A Systematic Review. (Pubmed Central) - Oct 24, 2023
This included the four Food and Drug Administration (FDA)-approved medications erenumab, galcanezumab, fremanezumab, and eptinezumab...The results further imply that combination treatment with CGRP antibodies and onabotulinumtoxinA may enhance the prevention of migraine in adults...Additionally, the study discovered considerable variances in effectiveness amongst various groups. However, further investigation is required to establish the best time and dosage and the effect of patient characteristics on the effectiveness and safety of these medications.
- |||||||||| Aimovig (erenumab-aooe) / Amgen, Novartis
Trial completion, Trial completion date, Trial primary completion date: COLLIDE: Effect of Levcromakalim in Individuals With Migraine Pretreated With Erenumab (clinicaltrials.gov) - Oct 23, 2023
P=N/A, N=16, Completed,
However, further investigation is required to establish the best time and dosage and the effect of patient characteristics on the effectiveness and safety of these medications. Recruiting --> Completed | Trial completion date: Feb 2024 --> Jun 2023 | Trial primary completion date: Feb 2024 --> Jun 2023
- |||||||||| Aimovig (erenumab-aooe) / Amgen, Novartis
Trial completion, Trial completion date, Trial primary completion date: COMPETE: Effect of Sildenafil in Individuals With Migraine Pretreated With Erenumab (clinicaltrials.gov) - Oct 23, 2023
P=N/A, N=16, Completed,
Recruiting --> Completed | Trial completion date: Feb 2024 --> Jun 2023 | Trial primary completion date: Feb 2024 --> Jun 2023 Recruiting --> Completed | Trial completion date: Feb 2024 --> Oct 2023 | Trial primary completion date: Feb 2024 --> Oct 2023
- |||||||||| Emgality (galcanezumab) / Eli Lilly, Daiichi Sankyo, Ajovy (fremanezumab) / Otsuka, Teva, Aimovig (erenumab-aooe) / Amgen, Novartis
Journal: Patterns of anti-CGRP mAbs use and variation of triptan consumption following treatment initiation: A descriptive drug utilization study in the Tuscany region, Italy. (Pubmed Central) - Oct 13, 2023
Overall, findings seem to indicate a favorable tolerability and effectiveness profile. Further studies are warranted to better establish the long-term comparative effectiveness, safety, and cost effectiveness of anti-CGRP mAbs compared to other preventive medications.
- |||||||||| Sylvant (siltuximab) / Jazz, Aimovig (erenumab-aooe) / Amgen, Novartis
Enrollment open, Trial initiation date: Screening Trial for Pain Relief in Schwannomatosis (STARFISH) (clinicaltrials.gov) - Oct 9, 2023
P2, N=40, Recruiting,
Further studies are warranted to better establish the long-term comparative effectiveness, safety, and cost effectiveness of anti-CGRP mAbs compared to other preventive medications. Not yet recruiting --> Recruiting | Initiation date: Mar 2023 --> Aug 2023
- |||||||||| botulinum neurotoxin type A gel formulation (RT001) / Revance Therap, Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Retrospective data, Journal, Real-world evidence, Real-world: Real-world persistence and costs among patients with chronic migraine treated with onabotulinumtoxinA or calcitonin gene-related peptide monoclonal antibodies. (Pubmed Central) - Oct 4, 2023
The data will be accessible for 12 months, with possible extensions considered. For more information on the process, or to submit a request, visit the following link: https://www.abbvieclinicaltrials.com/hcp/data-sharing/.
- |||||||||| Aimovig (erenumab-aooe) / Amgen, Novartis
Clinical, Journal: Monoclonal Antibodies Targeting CGRP: A Novel Treatment in Vestibular Migraine. (Pubmed Central) - Sep 28, 2023
As a comparison, we considered the same VM patients during conventional migraine treatments (i.e., propranolol, flunarizine, or valproic acid), which were tried before mAbs therapy...Treatment with anti-CGRP mAbs may be effective in VM patients who did not respond to conventional migraine treatments. These findings should be tested in large, randomized clinical trials.
- |||||||||| Emgality (galcanezumab) / Eli Lilly, Daiichi Sankyo, Ajovy (fremanezumab) / Otsuka, Teva, Aimovig (erenumab-aooe) / Amgen, Novartis
Journal, Real-world evidence, Real-world: Medication Overuse Headache, Chronic Migraine and Monoclonal Antibodies Anti-CGRP: A Real-World Study. (Pubmed Central) - Sep 25, 2023
This comparative review may help the healthcare providers in choosing the best pharmacotherapeutic agent for their patients based on patient-specific information. The small number of patients included in each group and the open design do not allow definitive conclusions, but the use of anti-CGRP monoclonal antibodies in patients with CM and MOH may result in lessening the number of headache days when compared with conventional treatment with drugs.
- |||||||||| Aimovig (erenumab-aooe) / Amgen, Novartis
Journal: Evaluation of Vestibular Functions in a Case of Vestibular Migraine With Successful Treatment With Erenumab. (Pubmed Central) - Sep 25, 2023
The sensorineural hearing loss in pure-tone audiometry, dysfunctions shown in vestibular examinations (cervical and ocular vestibular evoked myogenic potentials), and mild endolymphatic hydrops shown in gadolinium-enhanced inner ear magnetic resonance imaging, all in the right ear, revealed no change compared with those observed before treatment. This case suggests that VM may be treated by blocking CGRP in the trigeminal ganglion, which suppresses the effects on the vestibular nucleus; herein, no effects were observed in the inner ear despite the clear amelioration of dizziness.
- |||||||||| Clinical, Observational data, Retrospective data, Review: Effectiveness of Calcitonin Gene-Related Peptide Monoclonal (Pubmed Central) - Sep 25, 2023
This case suggests that VM may be treated by blocking CGRP in the trigeminal ganglion, which suppresses the effects on the vestibular nucleus; herein, no effects were observed in the inner ear despite the clear amelioration of dizziness. The use of calcitonin gene-related peptide antibodies in real-world studies to prevent migraine demonstrates promising effectiveness outcomes, in agreement with those reported in previously published randomized
- |||||||||| Ubrelvy (ubrogepant) / AbbVie, Ajovy (fremanezumab) / Otsuka, Teva, Aimovig (erenumab-aooe) / Amgen, Novartis
Journal: A Bibliometric and Scientific Knowledge Map Study of Migraine Treatment from 2013 to 2022. (Pubmed Central) - Sep 21, 2023
The current research mainly focuses on CGRP-related therapeutics, such as fremanezumab, erenumab and ubrogepant. Based on the analysis of bibliometric data on migraine treatment over the past decade, the trends and the knowledge graph of the country, organization, author, reference, and the keyword were identified, providing accurate and quick positioning of the critical information in the domain.
- |||||||||| Aimovig (erenumab-aooe) / Amgen, Novartis
Trial completion date, Trial primary completion date: Multidisciplinary Translational Approach to Investigate Mechanisms Predictors & Prevention of Persistent PTH (clinicaltrials.gov) - Sep 7, 2023
P2, N=112, Recruiting,
About 1/3 of patients with treatment refractory chronic migraine who have a disappointing response to erenumab and switch to fremanezumab, obtained a meaningful and sustained improvement of their migraine load over time, supporting the appropriateness of this therapeutic approach in clinical practice. Trial completion date: Aug 2023 --> Aug 2024 | Trial primary completion date: Aug 2023 --> Aug 2024
- |||||||||| Aimovig (erenumab-aooe) / Amgen, Novartis
Case of the Shakes (Exhibit Hall) - Aug 23, 2023 - Abstract #ASA2023ASA_4988;
Carbamazine was started and her DBS current increased slightly with full resolution of her symptoms. The etiology remains unclear.
- |||||||||| Reyvow (lasmiditan) / Eli Lilly, Daiichi Sankyo, Qulipta (atogepant) / AbbVie, Aimovig (erenumab-aooe) / Amgen, Novartis
Journal: New therapeutic options for migraine. (Pubmed Central) - Aug 22, 2023
The etiology remains unclear. No abstract available
- |||||||||| Aimovig (erenumab-aooe) / Amgen, Novartis
Trial completion: Erenumab for Idiosyncratic Facial Pain (clinicaltrials.gov) - Aug 14, 2023
P4, N=29, Completed,
Its ability to antagonise CGRP activity at both receptors may be useful in better understanding the clinical profile of erenumab. Active, not recruiting --> Completed
|
